Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EBNK-001
- Development stage
- Phase 2
- Lead developer
- Essen Biotech
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
EBNK-001 is an investigational allogeneic natural killer (NK) cell therapy developed by Essen Biotech for the treatment of advanced or metastatic solid tumors. The therapy utilizes donor-derived NK cells that are administered to patients following a lymphodepletion regimen consisting of cyclophosphamide and fludarabine. To enhance the persistence and anti-tumor activity of the infused cells, the treatment is supported by low-dose interleukin-15 (IL-15). EBNK-001 is currently being evaluated in Phase 1/2 clinical trials both as a monotherapy and in combination with the PD-1 checkpoint inhibitor pembrolizumab to leverage synergistic immune activation against various solid malignancies.
Beyond the preview
Go deeper on EBNK-001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EBNK-001.